What is Leerink Partnrs’ Estimate for Veracyte Q1 Earnings?

Veracyte, Inc. (NASDAQ:VCYT) – Equities research analysts at Leerink Partnrs lowered their Q1 2025 earnings estimates for Veracyte in a report issued on Monday, April 21st. Leerink Partnrs analyst P. Souda now expects that the biotechnology company will post earnings per share of $0.08 for the quarter, down from their previous estimate of $0.11. The consensus estimate for Veracyte’s current full-year earnings is $0.68 per share. Leerink Partnrs also issued estimates for Veracyte’s Q3 2025 earnings at $0.23 EPS.

VCYT has been the subject of several other research reports. Craig Hallum initiated coverage on shares of Veracyte in a research note on Thursday, March 20th. They set a “buy” rating and a $45.00 price target for the company. UBS Group upped their target price on shares of Veracyte from $46.00 to $49.00 and gave the company a “buy” rating in a research report on Tuesday, February 25th. Guggenheim reduced their price target on Veracyte from $45.00 to $37.00 and set a “buy” rating on the stock in a research report on Wednesday, April 9th. Needham & Company LLC reaffirmed a “buy” rating and set a $51.00 price objective on shares of Veracyte in a research note on Tuesday, February 25th. Finally, Stephens reissued an “overweight” rating and issued a $45.00 target price on shares of Veracyte in a research note on Wednesday, March 26th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, Veracyte has a consensus rating of “Moderate Buy” and a consensus price target of $42.60.

Veracyte Stock Performance

Shares of VCYT opened at $32.14 on Thursday. The business’s fifty day moving average price is $32.41 and its two-hundred day moving average price is $37.29. The firm has a market capitalization of $2.51 billion, a price-to-earnings ratio of -214.27 and a beta of 2.03. Veracyte has a 52 week low of $19.09 and a 52 week high of $47.32.

Veracyte (NASDAQ:VCYT) last issued its quarterly earnings data on Monday, February 24th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.29 by $0.07. Veracyte had a positive return on equity of 3.02% and a negative net margin of 2.18%. The firm had revenue of $118.63 million during the quarter, compared to the consensus estimate of $110.73 million. During the same quarter in the previous year, the company posted ($0.39) EPS.

Institutional Investors Weigh In On Veracyte

Several large investors have recently made changes to their positions in VCYT. Artisan Partners Limited Partnership raised its position in Veracyte by 31.4% during the fourth quarter. Artisan Partners Limited Partnership now owns 6,599,264 shares of the biotechnology company’s stock worth $261,331,000 after acquiring an additional 1,576,432 shares in the last quarter. Marshall Wace LLP increased its stake in shares of Veracyte by 768.9% during the 4th quarter. Marshall Wace LLP now owns 956,577 shares of the biotechnology company’s stock worth $37,880,000 after purchasing an additional 846,487 shares during the last quarter. Driehaus Capital Management LLC raised its holdings in shares of Veracyte by 226.8% in the 4th quarter. Driehaus Capital Management LLC now owns 1,183,766 shares of the biotechnology company’s stock valued at $46,877,000 after purchasing an additional 821,554 shares during the period. Point72 Asset Management L.P. acquired a new stake in Veracyte in the 4th quarter valued at about $20,717,000. Finally, Vanguard Group Inc. grew its holdings in Veracyte by 6.0% during the fourth quarter. Vanguard Group Inc. now owns 8,211,612 shares of the biotechnology company’s stock worth $325,180,000 after purchasing an additional 463,098 shares during the period.

About Veracyte

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.